Close menu




Biotechnology

Photo credits: pixabay.com

Commented by Juliane Zielonka on March 29th, 2022 | 13:34 CEST

Valneva, Triumph Gold, BioNTech - Gold rush mood in the pipeline

  • Gold
  • Biotechnology

While the Corona measures are eased in Spain, and the government lets symptom-free positive tested persons out of quarantine, Germany tightens again and extends the measures. This could create a gold-rush mood among BioNTech investors, as figures from the Mainz-based biotech Company will be announced on Wednesday. Valneva is also looking ahead with confidence to the first shipment of its liquid gold in the form of the COVID-19 inactivated vaccine. For investors with a more earthy disposition, it is a good idea to look at the real precious metals and gold deposits these days. For example, an investment in Canada's Triumph Gold Corporation offers copper and diamond deposits in addition to gold. The Company specializes in the discovery and development of gold and other valuable commodity deposits.

Read

Commented by Stefan Feulner on March 24th, 2022 | 13:07 CET

BioNTech, Cardiol Therapeutics, Moderna - New target groups to boost business

  • Biotechnology

Infection figures remain at record levels. Health authorities reported 283,732 new infections to the Robert Koch Institute, 21,139 cases more than a week ago. In contrast, the pace of vaccination is limping, with the vaccination status of the overall population changing only marginally and remaining at 75.8% basic immunization. Chancellor Scholz is now calling for compulsory vaccination to counter the threat of another wave of Corona in the fall. This message is likely to be grist to the mill for the vaccine manufacturers, whose ratings, similar to the vaccination rates, have dropped sharply in recent weeks.

Read

Commented by Nico Popp on March 22nd, 2022 | 11:22 CET

In the right place at the right time: BioNTech, Defence Therapeutics, Bayer

  • Biotechnology

For years, the pandemic has kept the world on tenterhooks. Currently, the epidemic is taking a break, at least in the media. But while the world is looking tautly at Ukraine and more and more refugees are arriving in Germany, the Omicron figures are rising once more. In some cases, the incidence in Germany is over 3,000. Although fewer and fewer people are dying, more people than ever are in quarantine. We look at BioNTech, a typical pandemic stock, and present other exciting investments from the healthcare sector.

Read

Commented by André Will-Laudien on March 21st, 2022 | 13:10 CET

Attention - MorphoSys, Valneva, CureVac, MAS Gold: These shares smell of a turnaround!

  • Gold
  • Biotechnology

The biotech sector, especially around vaccine manufacturers, has recently fallen somewhat out of fashion - Germany's most extensive Corona measures have likely already taken place. The general willingness to vaccinate can hardly be increased, and the vaccination obligation was dropped without a trace after lawyers formed a massive wave of lawsuits. But now that the Omicron infection figures are exploding to unimagined heights, we can expect a hot autumn again after a summer with a breather. "Corona has come to stay!" said Karl Lauterbach when he was not yet health minister. We take a look at some shares that have recently rebounded strongly.

Read

Commented by Carsten Mainitz on March 14th, 2022 | 12:47 CET

BioNTech, Defence Therapeutics, MorphoSys - Shares with blockbuster potential!

  • Biotechnology

Developing a blockbuster drug is the highest achievement in the pharmaceutical industry. A blockbuster is defined as a drug that can generate more than USD 1 billion in revenues per year. According to experts, the vaccine Comirnaty, developed by BioNTech and Pfizer, is likely to have brought in sales of well over USD 30 billion, thus clearly breaking the blockbuster barrier. Outside of vaccine research, there are also numerous companies with high long-term potential.

Read

Commented by Armin Schulz on March 7th, 2022 | 13:05 CET

Valneva, Defence Therapeutics, MorphoSys - Blockbuster potential

  • Biotechnology

Every pharmaceutical or biotech company wants a blockbuster. This term refers to a drug that generates annual sales of at least USD 1 billion. The best-known blockbuster drug currently is the Corona vaccine from BioNTech. In 2020, the rheumatism drug Humira was in the top spot with sales of over USD 20 billion. The Mainz-based vaccine manufacturer is likely to have significantly surpassed this mark in 2021. If a company hits the big time, it can reap the rewards for 20 years before the patent expires. Today, we take a look at three companies that have potential blockbusters.

Read

Commented by Stefan Feulner on March 4th, 2022 | 13:33 CET

Bayer, Defence Therapeutics, Merck KGaA - At the start of the trend

  • Biotechnology

The biotech industry is the innovative engine for a pharmaceutical industry dependent on new concepts due to the shift from blockbuster products to personalized medicine. Even before Corona, more than EUR seven billion per year was invested in R&D in 2019. The development of new drugs is particularly important for the pharmaceutical industry, as patent protection for many blockbuster drugs is expiring or has already expired. For this reason, the pharmaceutical industry is now much more often entering biotech companies in the early development phases of a new drug. The example of vaccine manufacturers has successfully highlighted this strategy, which will also be applied to other diseases in the future.

Read

Commented by Juliane Zielonka on March 3rd, 2022 | 13:12 CET

Cardiol, BioNTech, Novartis - Inventory at three high-flyers

  • CBD
  • Biotechnology

Good news, this time from Cardiol Therapeutics. Both the US FDA and regulatory authorities in Brazil and Mexico have given the green light for the inclusion of patients already vaccinated against COVID-19 in the LANCER trial. The opening with respect to this patient group increases the likelihood of a speedy trial completion. The pandemic cannot be over until global efforts are made to fight the virus together. So BioNTech will build a plant in Rwanda. And Novartis, as an experienced Big Pharma giant, illustrates through its quarterly figures how valuable the pharmaceutical industry as a whole can be as an investment.

Read

Commented by Armin Schulz on March 2nd, 2022 | 11:24 CET

BioNTech, XPhyto Therapeutics, Valneva - Where are the Corona winners?

  • Biotechnology

Even if the Corona coverage, which has prevailed for 2 years, has recently been replaced by the Ukraine conflict, the pandemic is not yet over. RKI chief Wieler recently reported increased outbreaks in nursing homes and rising incidences among the elderly. Health Minister Lauterbach also sees the wave not yet broken and reports the highest death rates in months. Since the legal basis for the Corona measures expires on March 19, a new law has been introduced to allow measures to be enacted beyond that date. Which companies could benefit?

Read

Commented by Carsten Mainitz on February 24th, 2022 | 11:30 CET

SYNLAB, XPhyto, Novavax - How long will the Corona boom last?

  • Biotechnology

Corona has been turning the world upside down for two years. Although the stock markets have largely recovered from their crash in February and March 2020 and are clearly up again, some stocks are still doing much better, thanks to Corona. For example, shares of companies involved in developing and producing Corona vaccines, medicines, or testing methods have significantly outperformed the indices. But how sustainable is this boom?

Read